尿路感染症に対するオーグペニン(Clavulanic acid-Ticarcillin)の臨床的検討 : 特にβ-lactamase産生菌に対する検討

Abstract

clavulanic acid(CVA)とticarcillin(TIPC)を1:15の比率で配合した注射用抗生物質オーグペニン(R)の尿路感染症に対する臨床的有用性を検討した。複雑性尿路感染症33例と急性単純性腎盂腎炎7例の合計40症例に本剤一回1.6gをブドウ糖液または電解質液100mlに溶解して, 一日に2回点滴静注を行った。急性腎盂腎炎に対する総合臨床効果は, 著効6例, 有効1例であり, 有効率100%であった。複雑性尿路感染症に対する総合臨床効果では, 著効14例, 有効9例, 無効2例, 有効率92.0%であった。自他覚的副作用は認められなかったが, 2症例において本薬剤に関連すると思われる一過性のGOT, GPTの上昇を認めた

Augpenin contains ticarcillin (TIPC) and clavulanic acid (CVA), at a ratio of 15:1. The beta-lactamase inhibitor, CVA, has been added to protect the TIPC from inactivation by beta-lactamase. To investigate the drug efficacy and safety against urinary tract infections (UTI), Augpenin was administered to 33 patients with chronic complicated UTI and 7 patients with acute pyelonephritis. Thirty two cases were evaluable by the UTI criteria. Excellent results were obtained in 6 of the cases of acute pyelonephritis, and moderate results in 1 case, with an overall effectiveness rate of 100%. Excellent results were obtained in 14 of the cases of chronic complicated UTI, moderate results in 9 cases, and poor results in 2 cases, with an overall effectiveness rate of 92%. No adverse reactions were noted, but a transient elevation of glutamic oxaloacetic transaminase and glutamic pyruvic transaminase levels was observed in 2 cases.